Browse Complete Report For More Information @
https://www.coherentmarketinsights.com/ongoing-insight/thrombocytopenia-treatment-market-
1484
Another drug Eltrombopag by Novartis, an oral, non-peptide thrombopoietin receptor agonist
has shown efficacy and safety for patients suffering from chronic immune thrombocytopenia
(CIT). The use of this drug is approved in the U.S and registered in Europe. The low dose of
Eltrombopag is effective and safe for the prevention of CIT. Case Reports Hematology, 2017,
reports that long-term usage of thrombopoetin (TPO) receptor agonists is safe for patients
suffering from chronic lymphocytic leukemia associated with Immune thrombocytopenia, as they
are a non-immunosuppressive drugs.
Global Thrombocytopenia Treatment Market Dynamics
The thrombocytopenia treatment market is driven by increasing prevalence of thrombocytopenia
globally. The risk of developing thrombocytopenia is much higher for chronic Hepatitis C cases.
In 2014, according to World Health Organization (WHO), the prevalence of Hepatitis C was
lower in Americas and Europe as compared to Africa and Pakistan, where the prevalence of
chronic liver disorder was 4-6 % higher than that in Americas and Europe. Liver disease has
become a socio economic and global health problem, as 60-80% of the population develops the
disease. Furthermore, increasing government support for fast-track approval to discover newer
treatments for this disorder and increasing investment in the development of new drugs by
biotechnology and pharmaceutical companies are expected to propel growth of the
thrombocytopenia treatment market during the forecast period. However, from 2023,
thrombocytopenia treatment market is projected to witness a slowdown in growth due to patent
expiration and increasing availability of generics of Promacta and MabThera.
Global Thrombocytopenia Treatment Market – Competitors
Major players in thrombocytopenia treatment market include 3SBio Inc., Amarillo Biosciences,
Inc., Amgen Inc., Baxalta Incorporated, Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers
Squibb Company, Cellerant Therapeutics, Inc., Eisai Co., Ltd., Hansa Medical AB, Intas
Pharmaceuticals Ltd., Merck & Co., Inc., Momenta Pharmaceuticals, Inc., Myelo Therapeutics
GmbH, Neumedicines Inc., Novartis AG, Pfizer Inc., Prophylix Pharma AS, Rigel
Pharmaceuticals, Inc., Shionogi & Co., Ltd., STATegics, Inc., and ViroMed Co., Ltd.
To Get Instant Access, Purchase Report Here @ https://www.coherentmarketinsights.com/insight/
buy-now/1484